JAX strives to advance rare disease research and treatment options

For the past six years, the JAX Rare Disease Translational Center has worked with dozens of rare disease foundations to create custom mouse models that represent rare medical conditions, the majority of which present in young children.

In May 2022, JAX appointed Cathleen (Cat) Lutz, Ph.D., M.B.A. as Vice President of the Rare Disease Translational Center, marking an important step forward in its commitment to rare disease research. The expansion positions the Center to play an integral role throughout the entire rare disease odyssey, from diagnosis to research to drug development. The Center also collaborates closely with biotech and pharmaceutical companies to accelerate the path to drug discovery for these debilitating conditions. By taking a more holistic approach, the Center will make a significant impact on the experience of those living with rare diseases. Read more

Related Posts

On the Record: Startup aims to turn scientific researchers into ‘deep-tech’ entrepreneurs

Justin Hafner, founder and former CEO of digital health startup Kinotek, aims to make an even bigger splash in the startup world...

3 November 2025

Skincare startup funds UMaine scholarship to spark innovation

Marin Skincare, known for its Lobster Lotion product, partnered with the University of Maine to create a scholarship to spur innovation and...

29 October 2025

Bigelow Lab looks to create ‘blue’ biotechnology businesses and jobs

Bigelow Laboratory for Ocean Sciences, an East Boothbay nonprofit research institute focused on global ocean health, last week launched a program...

28 October 2025